1
|
Ranjbar H, Soti M, Kohlmeier KA, Sheibani V, Ahmadi-Zeidabadi M, Rafiepour K, Shabani M. The cannabinoid antagonist, AM251 attenuates ataxia related deficiencies in a cerebellar ataxic model. Int J Neurosci 2024; 134:522-529. [PMID: 36120979 DOI: 10.1080/00207454.2022.2126771] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2022] [Revised: 08/21/2022] [Accepted: 08/29/2022] [Indexed: 10/14/2022]
Abstract
Aim: Disruption in cerebellar inputs, as well as dysfunction of Purkinje cells (PCs), causes a change in the timing of electrical signaling in the cerebellum resulting in disorders such as cerebellar ataxia. Although much clinical and molecular genetics research has been conducted to understand this disorder, there is no specific treatment for cerebellar ataxia. As cannabinoid type 1 receptors (CB1Rs) are highly expressed in the cerebellum and have been suggested as a therapeutic strategy, we determined whether AM251, a cannabinoid receptor antagonist, was neuroprotective of PCs in a rat cerebellar ataxic model.Materials and methods: To this end, we conducted behavioral and histological tests in the 3-acetylpyridine (3AP) rat cerebellar ataxia model, to explore whether AM251 was protective against induction of ataxia and cell death.Results: Rats with chemical degeneration of the inferior olive induced by 3AP (55 mg/kg, i.p.) clearly showed cerebellar ataxic symptoms. The locomotor activity and motor coordination of the ataxic animals were clearly disrupted compared to the control group. Further, histological analysis showed cell death and PCs degenerated with loss of cell membrane integrity associated with 3AP. Pre-treatment by AM251 improved the locomotor activity of the ataxic animals, and AM251 almost prevented PCs neuronal degeneration.Conclusion: Our data which show protection of cerebellar PCs and motor improvement in the ataxic rat model by treatment with AM251 suggests that targeting cannabinoid receptors should be considered for therapeutic intervention in cerebellar ataxia.HIGHLIGHTS:AM251 was protective against induction of ataxia and cell death.CBR antagonist typically ameliorated 3AP induced Ataxia.AM251 affected explorative and gait disturbances induced by 3AP.CBR antagonist improved impairments of anxiety-like behaviors following 3AP.
Collapse
Affiliation(s)
- Hoda Ranjbar
- Neuroscience Research Center, Neuropharmacology Institute, Kerman University of Medical Sciences, Kerman, Iran
| | - Monavareh Soti
- Neuroscience Research Center, Neuropharmacology Institute, Kerman University of Medical Sciences, Kerman, Iran
| | - Kristi A Kohlmeier
- Department of Drug Design and Pharmacology, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark
| | - Vahid Sheibani
- Neuroscience Research Center, Neuropharmacology Institute, Kerman University of Medical Sciences, Kerman, Iran
| | - Meysam Ahmadi-Zeidabadi
- Neuroscience Research Center, Neuropharmacology Institute, Kerman University of Medical Sciences, Kerman, Iran
| | - Kiana Rafiepour
- Neuroscience Research Center, Neuropharmacology Institute, Kerman University of Medical Sciences, Kerman, Iran
| | - Mohammad Shabani
- Neuroscience Research Center, Neuropharmacology Institute, Kerman University of Medical Sciences, Kerman, Iran
| |
Collapse
|
2
|
Goudarzi I, Kaffashian M, Shabani M, Haghdoost-Yazdi H, Behzadi G, Janahmadi M. In vivo 4-aminopyridine treatment alters the neurotoxin 3-acetylpyridine-induced plastic changes in intrinsic electrophysiological properties of rat cerebellar Purkinje neurones. Eur J Pharmacol 2010; 642:56-65. [DOI: 10.1016/j.ejphar.2010.05.031] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2009] [Revised: 04/29/2010] [Accepted: 05/25/2010] [Indexed: 12/30/2022]
|
3
|
Abstract
Impairments of glucose and mitochondrial function are important causes of brain dysfunction and therefore of brain disease. Abnormalities have been found in association with disease of the nervous system in most of the components of glucose/mitochondrial metabolism. In many, molecular genetic abnormalities have been defined. Brain glucose oxidation is abnormal in common diseases of the nervous system, including Alzheimer disease and other dementias, Parkinson disease, delirium, probably schizophrenia and other psychoses, and of course cerebrovascular disease. Defects in a single component and even a single mutation can be associated with different clinical phenotypes. The same clinical phenotype can result from different genotypes. The complex relationship between biological abnormality in brain glucose utilization and clinical disorder is similar to that in other disorders that have been intensively studied at the genetic level. Genes for components of the pathways of brain glucose oxidation are good candidate genes for disease of the brain. Preliminary data support the proposal that treatments to normalize abnormalities in brain glucose oxidation may benefit many patients with common brain diseases.
Collapse
Affiliation(s)
- John P Blass
- Weill Medical College of Cornell University, Burke Medical Research Institute White Plains, New York 10605, USA
| |
Collapse
|
4
|
Parsons RB, Smith ML, Williams AC, Waring RH, Ramsden DB. Expression of nicotinamide N-methyltransferase (E.C. 2.1.1.1) in the Parkinsonian brain. J Neuropathol Exp Neurol 2002; 61:111-24. [PMID: 11853016 DOI: 10.1093/jnen/61.2.111] [Citation(s) in RCA: 64] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Nicotinamide N-methyltransferase (NNMT) has been proposed as a link between the environmental and genetic factors of Parkinson disease (PD). Therefore, we explored the hypothesis that high levels of NNMT expression may predispose to the development of PD. Regions of high mRNA expression were shown in the spinal cord, medulla, and temporal lobe, with lowest expression in the cerebellum, subthalamic nucleus, and caudate nucleus. Using 2 NNMT antibodies, the protein was shown to be expressed in multipolar neurons in the temporal lobe, caudate nucleus, and spinal cord, granular neurons of the cerebellum, dopaminergic neurons in the substantia nigra, and in the axons of the third nerve. Expression of NNMT was compared in PD and non-PD control cerebella and caudate nucleus. PD tissue exhibited significantly increased levels of NNMT protein and activity. PD disease duration was inversely correlated with the level of expression in cerebellum. This is the first demonstration that patients with PD have higher levels of NNMT activity and protein in brain tissue than those without PD and that NNMT expression is associated with neurons that degenerate in PD.
Collapse
Affiliation(s)
- Richard B Parsons
- Department of Medicine, University of Birmingham, Queen Elizabeth Hospital, Edgbaston, United Kingdom
| | | | | | | | | |
Collapse
|
5
|
Moss SJ, Wang G, Chen R, Pal R, Fowler SC. 3-acetylpyridine reduces tongue protrusion force but does not abolish lick rhythm in the rat. Brain Res 2001; 920:1-9. [PMID: 11716805 DOI: 10.1016/s0006-8993(01)02790-1] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Data from other laboratories suggest that neurons in the inferior olivary nucleus (IO) may play a role in the modulation of rhythmic tongue movements in rats. Because of its known harmful effects on neurons of the IO, it was suspected that administration of the neurotoxin 3-acetylpyridine (3AP) would affect subsequent tongue dynamics during rat licking. In the present study, the task of licking water from a force-transducing disk was investigated in water-restricted rats that received systemic administration of 3AP (12.5, 25, and 50 mg/kg). After recovery from the acute toxic effects of 3AP, tongue dynamics were assessed by measuring lick force, lick rhythm, variability of timing within bursts of licking, and number of licks per 2-min session. At 50 mg/kg, 3AP resulted in: (1) reduced lick force; (2) reduced number of licks; and (3) increased variance in the timing within bursts. Lick rhythm was not significantly affected by any dose of 3AP. All 3AP treatment groups and the vehicle control group displayed slowing of lick rhythm after harmaline challenge. Compared to vehicle controls, rats receiving lower and mid-range doses of 3AP displayed indistinguishable lick behaviors, with one exception--when the lick task was made incrementally more difficult by extending the distance required to make contact with the lick-disk, rats that had received 25 mg/kg 3AP persevered at the task more than all other rats. The various changes in lick dynamics may be due to the detrimental effects of 3AP at the IO, and possibly at the hypoglossal nucleus and other sites.
Collapse
Affiliation(s)
- S J Moss
- Department of Pharmacology and Toxicology, University of Kansas, Lawrence, KS 66045, USA
| | | | | | | | | |
Collapse
|
6
|
Kinoshita K, Watanabe Y, Asai H, Matsuoka Y. Metabolic abnormalities caused by 3-acetylpyridine in the cerebral motor regions of rats: partial recovery by thyrotropin-releasing hormone. JAPANESE JOURNAL OF PHARMACOLOGY 2000; 82:295-300. [PMID: 10875748 DOI: 10.1254/jjp.82.295] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Although 3-acetylpyridine (3-AP) induces several motor disturbances and it degenerates the olivocerebellar pathway, abnormalities caused by 3-AP in cerebral motor regions remain to be elucidated. Here we investigated the metabolic changes caused by 3-AP (75 mg/kg, i.p.) on local cerebral glucose utilization (LCGU) in various brain regions. The effects of anti-ataxic agents, thyrotropin-releasing hormone (TRH) (10 mg/kg, i.p.) and its mimetic agent taltirelin hydrate (1 mg/kg, i.p.), on the 3-AP-induced change in LCGU were also investigated. The LCGU in the nuclei of the basal ganglia, thalamus, limbic structures and brainstem of 3-AP-treated rats was significantly lower than that of naive animals. However 3-AP increased the LCGU of the cerebellar nuclei. TRH restored depressed LCGU in the substantia nigra and ventral tegmental area. TRH tended to restore the lowered LCGU in several nuclei of 3-AP-treated rats. Moreover, taltirelin further increased the LCGU in the cerebellar nuclei. These results suggest that the motor disturbance of the 3-AP-treated rats may be due to not only degeneration of the olivocerebellar pathway but also dysfunction of the several areas that play a role in motor coordination. Moreover, the anti-ataxic action by TRH could result from metabolic restoration of the multiple motor-coordination-related areas.
Collapse
Affiliation(s)
- K Kinoshita
- Pharmacology Department, Discovery Research Laboratory, Tanabe Seiyaku Co, Ltd, Toda, Saitama, Japan
| | | | | | | |
Collapse
|
7
|
Watanabe Y, Kinoshita K, Koguchi A, Yamamura M. A new method for evaluation of motor deficits in 3-acetylpyridine-treated rats. J Neurosci Methods 1997; 77:25-9. [PMID: 9402553 DOI: 10.1016/s0165-0270(97)00104-0] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
We established a novel method for quantitative evaluation of the motor deficits induced by 3-acetylpyridine (3-AP) in rats. 3-AP (75 mg/kg, i.p.) was injected in a time-controlled manner by a following injection of niacinamide (NIA; 300 mg/kg, i.p.). Changes in the motor function were evaluated by measuring the maximal height of vertical jump (MHVJ) to escape from an electrical shock on the foot, as well as ataxic gait. The MHVJ decreased and reached a minimum value 5-7 days after the 3-AP treatment. The close correlation of the MHVJ and the incidence of ataxic gait indicates that the decrease of MHVJ is a useful quantitative index of motor deficits.
Collapse
Affiliation(s)
- Y Watanabe
- Pharmaceutical Development Research Laboratory, Tanabe Seiyaku Company Limited, Saitama, Japan
| | | | | | | |
Collapse
|
8
|
Calingasan NY, Baker H, Sheu KF, Gibson GE. Selective enrichment of cholinergic neurons with the alpha-ketoglutarate dehydrogenase complex in rat brain. Neurosci Lett 1994; 168:209-12. [PMID: 8028777 DOI: 10.1016/0304-3940(94)90452-9] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
Numerous reports suggest a close interaction between acetylcholine homeostasis and oxidative metabolism. However, the neuroanatomical basis of this relationship has not been established. A previous study showed that a key mitochondrial enzyme, alpha-ketoglutarate dehydrogenase complex (KGDHC) occurs at low levels in neurons, glia and neuropil throughout the rat brain. Some regions including those that are enriched with a cholinergic neuronal marker, choline acetyltransferase (ChAT) show relatively high perikaryal enrichment of KGDHC. The current study utilized double label immunofluorescence to determine whether cholinergic neurons are enriched with KGDHC in rat brain. In cranial nerve nuclei, trapezoid nucleus, nucleus ambiguous and inferior olive, virtually all cholinergic neurons were enriched with KGDHC. However, in basal forebrain nuclei, only a subpopulation of cholinergic cells were intensely immunoreactive for KGDHC. These data provide morphological evidence to support the hypothesized link between cholinergic function and oxidative metabolism in specific brain regions.
Collapse
Affiliation(s)
- N Y Calingasan
- Cornell University Medical College, Burke Medical Research Institute, White Plains, NY 10605
| | | | | | | |
Collapse
|